Testing, Inspection and Certification Sector Outlook — September 2026
This report covers the Testing, Inspection and Certification sector across eight publicly traded companies, comparing forward valuation, segment mix and recorded transactions. It is written for owners, boards and acquirers assessing where their business sits between accredited inspection work and adjacent models.
For information only. Not an appraisal or a fairness opinion.
What moved since: Testing, Inspection and Certification M&A update, 14–28 September 2026
Key figures
- Outsourced inspection multiple
- 13.7x
- EV/EBITDA CY2027E, 3 rated names
- Adjacent models multiple
- 9.0x
- EV/EBITDA CY2027E, 4 rated names
- Sector median multiple
- 9.7x
- EV/EBITDA CY2027E, 7 rated names
- Mistras Group deal value
- $848M
- Enterprise value, H.I.G. Capital acquisition
Read the report
1 / 20 · INDUSTRIALS › COMMERCIAL AND PROFESSIONAL SERVICES › TESTING, INSPECTION AND CERTIFICATION
Executive summary
Testing, inspection and certification splits into two price levels: outsourced inspection trades at 13.7x forward EBITDA versus 9.0x for adjacent models, against a 9.7x sector median. The premium at the top of the range holds through a forward lens, concentrated in names — UL Solutions Inc. (ULS), Pearson plc (PSO), Sotera Health Company (SHC) — combining above-median margin with above-median multiple, which in our judgment points to mandated, recurring scope. Recorded transactions, including H.I.G. Capital's acquisition of Mistras Group, Inc. at $848M, priced nearer the middle.
Key findings
- Outsourced inspection prices at 13.7x forward EBITDA versus 9.0x for adjacent models.
- The top two names hold 15.0x while the bottom two sit at 7.2x, even on a forward basis.
- Above-median margin and above-median multiple meet in only three of seven rated names.
- Recorded deals price nearer this set's middle, not its top, per the six disclosed cases.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
INDUSTRIALS › COMMERCIAL AND PROFESSIONAL SERVICES › TESTING, INSPECTION AND CERTIFICATION
This is the cover for a September 2026 sector outlook on Testing, Inspection and Certification companies.
This report examines Testing, Inspection and Certification companies as of September 2026, valued primarily on EV/EBITDA for CY2027E. What follows shows why one label covers two very different price levels — so what to do about it depends on which half of the set your business sits in.
Everything on this page
INDUSTRIALS › COMMERCIAL AND PROFESSIONAL SERVICES › TESTING, INSPECTION AND CERTIFICATION Testing and Inspection: Two Halves, Two Price Levels Where the premium sits across eight testing, inspection and certification companies, how the two halves of the set are valued, and what the recorded transactions show. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This page lists the report's five sections plus an appendix.
We've built this report so the bottom line comes first — read section one and you have the whole story, then go deeper into the landscape, valuation, precedent transactions and strategic implications as you need them. So what: you can stop after the first section and still walk away with the decision-relevant conclusion.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line The Sector Prices in Two Halves, and the Ends Sort Cleanly 02 The Landscape Half the Set Sells Accredited Inspection Work, Half Sells Something Next to It 03 Valuation & Situations Where Each Name Sits in the Forward Range 04 Precedent Transactions What Buyers Agreed to Pay for Testing and Inspection Assets 05 Strategic Implications What This Means for the Company You Run 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Testing, Inspection and Certification Splits into Two Halves — Outsourced Inspection and Adjacent Models
This page summarizes the report's central finding: the sector splits into two valuation halves.
Testing, inspection and certification is really two markets under one label: outsourced inspection and verification services, and a set of adjacent models spanning equipment, labs, content and software. On EV/EBITDA for CY2027E, the outsourced inspection half sits above the adjacent models half, and that gap holds up even after accounting for growth already priced into a forward multiple. So what: before comparing yourself to a sector median, you need to know which half you're actually being compared against.
Everything on this page
01 · THE BOTTOM LINE Testing, Inspection and Certification Splits into Two Halves — Outsourced Inspection and Adjacent Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Two Halves of the Sector Sit at Two Price Levels Outsourced inspection and verification services accounts for 4 of the 8 companies; the 3 of those with a forward estimate sit at 13.7x on CY2027E EBITDA. The adjacent models half, also 4 companies and all 4 carrying a forward estimate, sits at 9.0x. 2 The Top of the Range Holds Its Premium Through a Forward Lens The two names at the top of the range sit at 15.0x and the two at the bottom at 7.2x. A CY2027E multiple already credits forecast growth, so a premium that survives that lens points to earnings buyers expect to still be there in the out years. 3 Above-Middle Margins and Above-Middle Multiples Sit Together in Three Names Three of the 7 names with a forward estimate sit above both the 9.7x middle of the range and the 25% margin mark: UL Solutions Inc. (ULS), Pearson plc (PSO) and Sotera Health Company (SHC). Our judgment, not something this screen measures: that pairing usually rests on mandated, recurring scope rather than on one-off volume. 4 What Buyers Agreed to Pay Sits Around the Middle of the Range Of the 6 recorded transactions, four carry a disclosed EBITDA multiple, spanning 6.7x to 12.2x. In the most recent, H.I.G. Capital agreed to acquire Mistras Group, Inc. at a recorded enterprise value of $848M. 9.7x Sector median EV/EBITDA CY2027E consensus · 7 rated of 8 companies 15.0x Premium end EV/EBITDA vs 7.2x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 6 Transactions with disclosed terms 17 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces section two, on how the sector splits into two halves.
Section two lays out who sits in each half of the set and how each half is valued. So what: this is where we establish the segment map that the rest of the valuation argument builds on.
Everything on this page
SECTION 02 02 THE LANDSCAPE Half the Set Sells Accredited Inspection Work, Half Sells Something Next to It Who is in each half, and how the two halves are valued. 02 of 06 Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Half the Set Is Accredited Inspection Work, and That Half Holds the Top of the Range
This page groups the approved companies by business segment and shows the median forward multiple for each group.
Half of this set of companies performs accredited inspection work, and that half holds the top of the valuation range on a median EV/EBITDA CY2027E basis. So what: segment membership, not company size, is the first signal of where a name should price.
Everything on this page
02 · MARKET MAP Half the Set Is Accredited Inspection Work, and That Half Holds the Top of the Range 8 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 OUTSOURCED INSPECTION AND VERIFICATION SERVICES 4 cos median 13.7x UL Solutions (ULS) TIC Solutions (TIC) Transcat (TRNS) Team (TISI) Accredited, repeat conformity assessment work sold as a service — the half of the set that holds both names at the top of the range. ADJACENT MODELS 4 cos median 9.0x Pearson (PSO) Sotera Health (SHC) Crane NXT (CXT) AudioEye (AEYE) Equipment, regulated laboratory capacity, assessment content and compliance platforms sold alongside accredited inspection work rather than as it.
- 0602 · LANDSCAPE
Accredited Inspection Work Prices Above the Adjacent Half of the Set
This page compares the accredited inspection segment against the adjacent-models segment on forward valuation.
Accredited inspection work prices above the adjacent half of the set on EV/EBITDA CY2027E medians, taken across rated names only. So what: the segment split introduced on the bottom line holds up when we look at the full landscape, not just the headline names.
Everything on this page
02 · LANDSCAPE Accredited Inspection Work Prices Above the Adjacent Half of the Set Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Outsourced inspection and verification services 4 50% 13.7x UL Solutions Inc. (ULS) · TIC Solutions, Inc. (TIC) · +2 more Accredited work, recurring by design. Four companies, 50% of the set, of which UL Solutions Inc. (ULS), Transcat, Inc. (TRNS) and TIC Solutions, Inc. (TIC) carry a forward estimate and sit at 13.7x; Team, Inc. (TISI) is shown on the page without one. Revenue here renews through surveillance audits and recertification cycles, and accredited scope is slow to stand up from scratch. Adjacent models 4 50% 9.0x Pearson plc (PSO) · Sotera Health Company (SHC) · +2 more Sold alongside the accredited work. Four companies — Pearson plc (PSO), Sotera Health Company (SHC), Crane NXT, Co. (CXT) and AudioEye, Inc. (AEYE) — all carrying a forward estimate, sitting at 9.0x. The group mixes equipment, licensed laboratory capacity, assessment content and compliance workflow software, so margin structures differ widely within it.
- 07SECTION 03
03
This divider introduces section three, the ranked valuation view across the rated companies.
Section three ranks every rated name on EV/EBITDA for CY2027E, from the top of the range to the bottom. So what: this is where we test whether the premium at the top is explained by growth already in the forward number, or by something else.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS Where Each Name Sits in the Forward Range The ranked view on EV / EBITDA for CY2027E, top of the range to bottom. 03 of 06 Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Top of the Range Holds a Premium That a Forward Multiple Already Credits
This page ranks all rated companies by EV/EBITDA for CY2027E against the sector median.
All rated companies sort by EV/EBITDA CY2027E against a sector median of 9.7x, and the top of the range holds a premium that this forward multiple already credits for expected growth. So what: a premium that survives a forward lens is a signal buyers expect durability, not just near-term momentum.
Everything on this page
03 · PUBLIC MARKET VALUATION The Top of the Range Holds a Premium That a Forward Multiple Already Credits EV / EBITDA (CY2027E) · all 7 rated companies, sorted descending · sector median 9.7x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 15.0x CORE · median 9.7x DISCOUNT · median 7.2x Sector median 9.7x WHAT SEPARATES THE TWO ENDS The top of the range. Two names sit at 15.0x on CY2027E EBITDA. Because the lens is forward, the forecast growth is already in the denominator, so a premium that survives it is associated with earnings buyers treat as durable rather than with a single strong year. The bottom of the range. Two names sit at 7.2x. Both sit in the adjacent models half of the set, where revenue leans on customer equipment budgets and software renewals rather than on accredited scope that a standard or an insurer requires. The two halves sort apart. The two companies at the top of the range both sit in outsourced inspection and verification services; the two at the bottom both sit in adjacent models. Seven of the 8 companies on the page carry a forward estimate, so the ranking rests on a small set and should be read as position, not as a verdict.
- 0903 · VALUATION DRIVERS
The Faster-Growing Half Holds the Higher Multiples, on Seven Names
This page splits the rated names into faster- and slower-growing cohorts, and higher- and lower-margin cohorts, and compares their median multiples.
On the rated names with estimates, the faster-growing cohort holds the higher multiples, and the same pattern shows on margin. So what: growth and margin move together with valuation in this set — an association the data supports, though we don't claim one causes the other.
Everything on this page
03 · VALUATION DRIVERS The Faster-Growing Half Holds the Higher Multiples, on Seven Names Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=3; higher-margin n=4; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 6% · EBITDA-margin split at 25% Split the Set at 6% Forward Growth and the Halves Price Apart The 4 names above the 6% line sit at 12.1x; the 3 names below it sit at 8.8x. That is an association across the 7 names with a forward estimate, on a base small enough that one company moves it — not a pricing rule. Margin on Its Own Does Not Track Position in the Range AudioEye, Inc. (AEYE) carries a 32% EBITDA margin and 10% forward growth and still sits at 6.1x, at the bottom of the range. Margin level and multiple move together in parts of this set and apart in others. Margin Structures Differ Far More than the Multiples Do Sotera Health Company (SHC) runs a 52% EBITDA margin and TIC Solutions, Inc. (TIC) a 16% one, yet the two sit closer together on the forward lens at 10.6x against 8.8x. Asset-heavy licensed capacity and people-intensive field work are different businesses that the same multiple can land on. What the Screen Cannot See Is What Diligence Spends Its Time On Our read, based on how these assets are underwritten: the mandated versus discretionary revenue mix, transferability of accredited scope on change of control, and the liability tail on certificates already issued sit behind names at both ends of this range. None of that is measured here, and all of it is testable inside a business.
- 1003 · SITUATION MAP
The Higher Multiples and the Wider Margins Sit Together in the Same Names
This page plots each rated name against the sector median multiple and the covered median margin to show where higher multiples and wider margins sit together.
Higher multiples and wider margins sit in the same names when we cut the set on the 9.7x sector median and the 25% margin mark. So what: this is an observation about where the set currently sits, not a recommendation to buy or sell any name.
Everything on this page
03 · SITUATION MAP The Higher Multiples and the Wider Margins Sit Together in the Same Names Cut on EV / EBITDA vs the sector median (9.7x) (rows) and EBITDA margin vs the covered median (25%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Above the Middle on Both Above-median multiple · above-median EBITDA margin 3 names UL Solutions Inc. (ULS) · Pearson plc (PSO) · Sotera Health Company (SHC) UL Solutions Inc. (ULS), Pearson plc (PSO) and Sotera Health Company (SHC) sit above the 9.7x middle of the range and above the 25% margin mark. For an owner, this is the position where pricing, renewal rates and mandated scope are already being credited, and the work is holding them through a slower demand year. Multiple Ahead of the Margin Above-median multiple · below-median EBITDA margin 1 names Transcat, Inc. (TRNS) Transcat, Inc. (TRNS) sits above the middle on the multiple and below it on margin. That combination puts the weight on conversion — realisation rate, technician utilisation and price escalators keeping pace with labour cost — because the margin has to catch up to what the forward lens is already carrying. Margin Ahead of the Multiple Below-median multiple · above-median EBITDA margin 1 names AudioEye, Inc. (AEYE) AudioEye, Inc. (AEYE) sits above the middle on margin and below it on the multiple. Where margin is wide and the multiple is not, the question an owner can answer is how much of the revenue base renews on its own and how concentrated it is by customer or end market. Below the Middle on Both Below-median multiple · below-median EBITDA margin 2 names Crane NXT, Co. (CXT) · TIC Solutions, Inc. (TIC) Crane NXT, Co. (CXT) and TIC Solutions, Inc. (TIC) sit below the middle on both measures. The levers here are mix and cost structure: which scopes carry recurring, mandated work, and which ones compete locally on price with little to defend them.
- 1103 · THE AGENDA
Margin Quality and Revenue Mix Are Where This Set's Multiples Separate
This page frames margin quality and revenue mix as the questions that separate multiples in this set.
Margin quality and revenue mix are where this set's multiples separate, and we frame these as the questions an owner or acquirer should resolve for their own business. So what: these are directional views grounded in the cohort data — a starting point for the conversation, not a recommendation.
Everything on this page
03 · THE AGENDA Margin Quality and Revenue Mix Are Where This Set's Multiples Separate NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Decide Which Scopes Get the Next Tranche of Capacity Capacity added in accredited, mandated scopes renews through surveillance and recertification cycles; capacity added in discretionary field work moves with customer budgets. Resolve which of the two the next laboratory, chamber or assessor bench serves. What changes the answer: A shift in the mandated share of revenue as scheme owners bring new standards into scope. Settle Build Versus Buy on Accredited Scope Standing up a new scope takes time and assessor capacity; buying one brings scope with a change-of-control approval attached. The answer turns on how long the organic route takes against the accreditation risk on the acquired route. What changes the answer: Evidence on whether a target's designations transfer, and how long integration onto a single accreditation takes. Price Against Labour Cost, Not Against Last Year In people-intensive scopes, escalators that lag technician cost show up in margin before they show up anywhere else. Review realisation rate and turnaround commitments alongside the contracted escalator on the largest accounts. What changes the answer: Realisation rate slipping while billable technician cost rises through the renewal cycle. Choose Which Half of the Set You Are Compared Against Revenue mix decides whether a company reads as outsourced inspection and verification services or as an adjacent model, and the two halves of this set are valued at different levels. Mix moves with what gets sold, priced and cross-sold, not with how the business is described. What changes the answer: Revenue shifting between accredited service delivery and product, content or software lines.
- 12SECTION 04
04
This divider introduces section four, on what buyers have agreed to pay for testing and inspection assets.
Section four reads recorded transactions for level and for buyer type. So what: precedent deals tell us where the market has actually cleared, which is a different question from where public multiples sit today.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS What Buyers Agreed to Pay for Testing and Inspection Assets Six recorded transactions, read for level and for buyer type. 04 of 06 Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Recent Transactions Were Agreed Near the Middle of the Range
This page walks through one of the transactions with disclosed terms as a case study.
We walk through recorded transactions with disclosed terms as case studies, with multiples read on LTM financials at announcement where disclosed. Deal multiples on this basis aren't directly comparable to the CY2027E public basis used elsewhere in this report, and no spread between the two is claimed. So what: precedent transactions give us a read on what buyers have actually paid, independent of where public trading multiples sit today.
Everything on this page
04 · DEAL CASE STUDIES Recent Transactions Were Agreed Near the Middle of the Range 1 of 6 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 19 precedent record(s) carry data-quality flags (deal value unit unresolved; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Sep-2026 $848M H.I.G. Capital H.I.G. Capital agreed to acquire Mistras Group, Inc. in the most recent transaction on the record. EV / LTM revenue 1.1x EV / LTM EBITDA 10.3x WHY THE DEAL HAPPENED The buyer is a financial sponsor and the target is an asset inspection business, which points to a buy-and-build around accredited field inspection capacity rather than a strategic extension of an existing scope. The size of the transaction suggests a platform purchase of the kind regional calibration and inspection assets are later assembled around. HOW THE TARGET WAS VALUED The transaction is recorded at an enterprise value of $848M, 10.3x EBITDA and 1.1x revenue, with value shown as recorded in the filing. That EBITDA level sits above the bottom of this set's forward range and below the top of it.
- 14SECTION 05
05
This divider introduces section five, on what the evidence means for the reader's own company.
Section five turns the evidence into operating moves, and names what would change the answer. So what: this is where the analysis becomes something you can act on.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS What This Means for the Company You Run The operating moves the evidence points to, and what would change the answer. 05 of 06 Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Three Patterns in This Set: Durable Margin, the Mix of Work, and Scale Added by Acquisition
This page sets out three patterns in the set — durable margin, mix of work, and scale added by acquisition — as questions for the next twelve months.
We see three patterns worth acting on: durable margin, the mix of work a company sells, and scale added by acquisition. So what: these are directional views on where to focus attention over the next twelve months, not a prediction of what will happen.
Everything on this page
05 · STRATEGIC IMPLICATIONS Three Patterns in This Set: Durable Margin, the Mix of Work, and Scale Added by Acquisition NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Grow the Part of Revenue That Renews on Its Own Across this set, the names above the middle of the range on both measures are the ones with mandated, repeating scope behind them. Concentrating sales effort and capacity on surveillance, recertification and cross-sell between testing, inspection and certification is the operating version of that position. FOR BOARDS Treat Accreditation and Liability as Capital Decisions Accredited scope, site density and the liability tail on issued certificates are what buyers underwrite in this sector, and they are set years before they show in earnings. Maintenance capital that keeps sites accredited belongs in the capital plan alongside growth capital, not below it. FOR ACQUIRERS Underwrite the Spread Between a Platform and a Bolt-on Four of the 6 recorded transactions carry a disclosed EBITDA multiple, and they sit near the middle of this set's forward range rather than at the top. Multi-site accredited scope and single-scope regional assets are different purchases, and the difference is worth pricing explicitly.
- 16SECTION 06
06
This divider introduces section six, the full comparables universe, methodology and sources.
Section six carries the comparables detail behind every figure in the body, the valuation basis, and where each disclosure lives. So what: everything shown earlier traces back to a source you can open.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier
This appendix lists the rated companies and the unrated company on EV/EBITDA for CY2027E, grouped by valuation tier.
This appendix carries every rated company against the 9.7x sector median, plus the one company without an eligible multiple. So what: every multiple used in the body of this report is here, at the company level, for you to check.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (9.7x); amber marks below · 7 rated companies; 1 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 7 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥12.1x · median 15.0x · 2 companies Transcat, Inc. TRNS Outsourced inspection and verification services $927M 16.3x 6% 15% 21 UL Solutions Inc. ULS Outsourced inspection and verification services $13.4B 13.7x 7% 28% 36 CORE — 8.5x–12.1x · median 9.7x · 3 companies Sotera Health Company SHC Regulated laboratory testing for devices and biologics $7.2B 10.6x 6% 52% 58 Pearson plc PSO Adjacent: assessment content and credentialing… $12.3B 9.7x 5% 25% 29 TIC Solutions, Inc. TIC Outsourced inspection and verification services $3.2B 8.8x 5% 16% 21 DISCOUNT — <8.5x · median 7.2x · 2 companies Crane NXT, Co. CXT Test, measurement and inspection equipment suppliers $4.0B 8.3x 6% 24% 30 AudioEye, Inc. AEYE Conformity data and compliance workflow platforms $93M 6.1x 10% 32% 42
- 1806 · PRECEDENT TRANSACTIONS (1 OF 1)
All Precedent Transactions with Disclosed Terms, Newest First
This appendix lists the transactions with disclosed terms, newest first.
We list the transactions with disclosed terms, newest first, with multiples read on LTM financials at announcement where disclosed. So what: this is the full record behind the deal case study, so you can weigh the pattern for yourself.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 6 transactions with disclosed terms in this tier (17 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 19 precedent record(s) carry data-quality flags (deal value unit unresolved; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Sep-2026 H.I.G. Capital → Mistras Group, Inc. $848M 1.1x 10.3x H.I.G. Capital agreed to acquire Mistras Group, Inc. in Sep-2026 at 10.3x EBITDA and 1.1x revenue; the transaction is recorded as announced, with value shown as recorded in the filing. Jan-2021 PerkinElmer, Inc. → Oxford Immunotec Global PLC n/a 7.3x n/a PerkinElmer, Inc. agreed to acquire Oxford Immunotec Global PLC in Jan-2021 at 7.3x revenue, announced. Regulated test businesses have been bought by instrument and diagnostics groups extending into verification. Nov-2018 SMTC Corporation → MC Test Service, Inc. n/a 0.5x 6.7x SMTC Corporation agreed to acquire MC Test Service, Inc. in Nov-2018 at 0.5x revenue and 6.7x EBITDA, announced. A small, single-scope test operation sits at a different level from a platform with multi-site accredited scope. Oct-2014 Engility Holdings, Inc. → TASC, Inc. n/a n/a 12.2x Engility Holdings, Inc. agreed to acquire TASC, Inc. in Oct-2014 at 12.2x EBITDA, announced. Even that level sits below the top of the current forward range for this set. Sep-2010 William Demant Holding A/S → Otix Global, Inc. n/a 0.7x n/a William Demant Holding A/S agreed to acquire Otix Global, Inc. in Sep-2010 at 0.7x revenue, announced, with value shown as recorded in the filing. The print is dated and is read here as context rather than as a current benchmark. n/a n/a → Team, Inc. n/a n/a 10.1x A transaction for Team, Inc. is recorded at 10.1x EBITDA with status announced and the acquirer recorded as n/a. Team, Inc. (TISI) is also one of the 8 companies on the valuation page.
- 1906 · METHODOLOGY
Sources, Assumptions and Data Quality
This page explains the report's sources, assumptions and data-quality treatment.
Every figure in this report links back to the record it was taken from, and where it doesn't, the appendix names the source and basis. So what: you can trace any number in this deck back to where it came from.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice 19 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Testing, Inspection and Certification and it clears the coverage gate with 7 of 8 companies (88%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 10 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 327 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (326) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 20
Two Price Levels Under One Sector Label, with the Gap Running Between and Within.
This closing page restates that one sector label covers two price levels, with companion tables available for further detail.
Two price levels sit under one sector label, and the gap runs both between the two halves and within each of them. So what: the companion tables carry the full universe and source index for any figure you want to trace further.
Everything on this page
Two Price Levels Under One Sector Label, with the Gap Running Between and Within. NeuraCap AI — Testing, Inspection and Certification Coverage September 2026 · Prepared by NeuraCap AI · Confidential Testing, Inspection and Certification Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20
Sources and methodology
This report covers Testing, Inspection and Certification (Industrials › Commercial and Professional Services › Testing, Inspection and Certification) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Testing, Inspection and Certification according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AudioEye, Inc. (AEYE), Crane NXT, Co. (CXT), Pearson plc (PSO), Sotera Health Company (SHC), TIC Solutions, Inc. (TIC), Team, Inc. (TISI), Transcat, Inc. (TRNS), UL Solutions Inc. (ULS). The market map groups them by business vertical — Outsourced inspection and verification services: 4 companies (ULS, TIC, TRNS, TISI); Adjacent models: 4 companies (PSO, SHC, CXT, AEYE). 7 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Testing, Inspection and Certification (Industrials › Commercial and Professional Services › Testing, Inspection and Certification) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Testing, Inspection and Certification according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AudioEye, Inc. (AEYE), Crane NXT, Co. (CXT), Pearson plc (PSO), Sotera Health Company (SHC), TIC Solutions, Inc. (TIC), Team, Inc. (TISI), Transcat, Inc. (TRNS), UL Solutions Inc. (ULS). The market map groups them by business vertical — Outsourced inspection and verification services: 4 companies (ULS, TIC, TRNS, TISI); Adjacent models: 4 companies (PSO, SHC, CXT, AEYE). 7 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
10 records failed a validation gate and never feed a statistic in this report (10 excluded from aggregate). Each exclusion, with its reason: AEYE — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TIC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TIC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TIC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TIC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TISI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TISI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TISI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TISI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · TRNS — EBITDA 46695.3819 is below the $1000000 materiality floor; any multiple would be meaningless (effect: excluded from aggregate)
Primary valuation basis and how it was chosen
Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Testing, Inspection and Certification and it clears the coverage gate with 7 of 8 companies (88%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 7 of 8 companies; EV / rEVenue: 8 of 8 companies; P/E: 6 of 8 companies. 2 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥12.1x, Core 8.5x–12.1x, Discount <8.5x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 9.7x = median(ev_ebitda CY2027E) (7 rated companies) · 15.0x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 9.7x = median(ev_ebitda CY2027E) within Core tier (n=3) · 7.2x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 12.1x = median(ev_ebitda CY2027E) | growth ≥ 6% (n=4) · 8.8x = median(ev_ebitda CY2027E) | growth < 6% (n=3) · 10.1x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 25% (n=4) · 8.8x = median(ev_ebitda CY2027E) | EBITDA margin < 25% (n=3) · 30% = median Rule of 40 score (revenue growth + EBITDA margin) (n=7)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Testing, Inspection and Certification recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 17 transactions were recorded for this industry; 6 are shown. 11 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 9 × deal value unit unresolved; 10 × no evidence record. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 331 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- UL Solutions (ULS) (sec.gov)
- TIC Solutions (TIC) (sec.gov)
- Transcat (TRNS) (sec.gov)
- Team (TISI) (sec.gov)
- Pearson (PSO) (sec.gov)
- Sotera Health (SHC) (sec.gov)
- Crane NXT (CXT) (sec.gov)
- AudioEye (AEYE) (sec.gov)
- $848M (sec.gov)
- n/a (sec.gov)
- 7.3x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Industrials
- M&A Update · 29 September 2026Tools and Hardware M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Tools and Hardware Sector Outlook — September 2026
- M&A Update · 29 September 2026Trading Companies and Distributors M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Trading Companies and Distributors Sector Outlook — September 2026
Want this analysis for a company in Testing, Inspection and Certification?
Company valuation reports run the same method against a single business — public or private.
